410 related articles for article (PubMed ID: 21795305)
1. The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside.
Choi HJ; Kim TY; Chung N; Yim JH; Kim WG; Kim JA; Kim WB; Shong YK
J Endocrinol; 2011 Oct; 211(1):79-85. PubMed ID: 21795305
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
3. The effect of 5-aminoimidazole-4-carboxamide-ribonucleoside was mediated by p38 mitogen activated protein kinase signaling pathway in FRO thyroid cancer cells.
Kim WG; Choi HJ; Kim TY; Shong YK; Kim WB
Korean J Intern Med; 2014 Jul; 29(4):474-81. PubMed ID: 25045295
[TBL] [Abstract][Full Text] [Related]
4. Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells.
Baumann P; Mandl-Weber S; Emmerich B; Straka C; Schmidmaier R
Exp Cell Res; 2007 Oct; 313(16):3592-603. PubMed ID: 17669398
[TBL] [Abstract][Full Text] [Related]
5. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.
Ball DW; Jin N; Rosen DM; Dackiw A; Sidransky D; Xing M; Nelkin BD
J Clin Endocrinol Metab; 2007 Dec; 92(12):4712-8. PubMed ID: 17878251
[TBL] [Abstract][Full Text] [Related]
6. AICAR inhibits proliferation and induced S-phase arrest, and promotes apoptosis in CaSki cells.
Guan TJ; Qin FJ; Du JH; Geng L; Zhang YY; Li M
Acta Pharmacol Sin; 2007 Dec; 28(12):1984-90. PubMed ID: 18031613
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of CYP2E1 induces HepG2 cells death by the AMP kinase activator 5'-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).
Zhuge J
Cell Biol Toxicol; 2009 Jun; 25(3):253-63. PubMed ID: 18473182
[TBL] [Abstract][Full Text] [Related]
8. Activation of AMP-kinase by AICAR induces apoptosis of DU-145 prostate cancer cells through generation of reactive oxygen species and activation of c-Jun N-terminal kinase.
Sauer H; Engel S; Milosevic N; Sharifpanah F; Wartenberg M
Int J Oncol; 2012 Feb; 40(2):501-8. PubMed ID: 22002081
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
[TBL] [Abstract][Full Text] [Related]
10. Role of AMP-activated protein kinase activators in antiproliferative multi-drug pituitary tumour therapies: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumour cells.
Tulipano G; Faggi L; Cacciamali A; Spinello M; Cocchi D; Giustina A
J Neuroendocrinol; 2015 Jan; 27(1):20-32. PubMed ID: 25323047
[TBL] [Abstract][Full Text] [Related]
11. BRAF is a therapeutic target in aggressive thyroid carcinoma.
Salvatore G; De Falco V; Salerno P; Nappi TC; Pepe S; Troncone G; Carlomagno F; Melillo RM; Wilhelm SM; Santoro M
Clin Cancer Res; 2006 Mar; 12(5):1623-9. PubMed ID: 16533790
[TBL] [Abstract][Full Text] [Related]
12. 5'-AMP-Activated Protein Kinase Regulates Papillary (TPC-1 and BCPAP) Thyroid Cancer Cell Survival, Migration, Invasion, and Epithelial-to-Mesenchymal Transition.
Cazarin JM; Coelho RG; Hecht F; Andrade BM; Carvalho DP
Thyroid; 2016 Jul; 26(7):933-42. PubMed ID: 27121619
[TBL] [Abstract][Full Text] [Related]
13. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
[TBL] [Abstract][Full Text] [Related]
14. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
Mitsiades CS; Negri J; McMullan C; McMillin DW; Sozopoulos E; Fanourakis G; Voutsinas G; Tseleni-Balafouta S; Poulaki V; Batt D; Mitsiades N
Mol Cancer Ther; 2007 Mar; 6(3):1070-8. PubMed ID: 17363500
[TBL] [Abstract][Full Text] [Related]
15. 5-aminoimidazole-4-carboxamide riboside enhances effect of ionizing radiation in PC3 prostate cancer cells.
Isebaert SF; Swinnen JV; McBride WH; Begg AC; Haustermans KM
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1515-23. PubMed ID: 21944462
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
[TBL] [Abstract][Full Text] [Related]
17. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
Friday BB; Yu C; Dy GK; Smith PD; Wang L; Thibodeau SN; Adjei AA
Cancer Res; 2008 Aug; 68(15):6145-53. PubMed ID: 18676837
[TBL] [Abstract][Full Text] [Related]
18. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
19. Uveal melanoma cell growth is inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase.
Al-Moujahed A; Nicolaou F; Brodowska K; Papakostas TD; Marmalidou A; Ksander BR; Miller JW; Gragoudas E; Vavvas DG
Invest Ophthalmol Vis Sci; 2014 Apr; 55(7):4175-85. PubMed ID: 24781943
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
Sengupta TK; Leclerc GM; Hsieh-Kinser TT; Leclerc GJ; Singh I; Barredo JC
Mol Cancer; 2007 Jul; 6():46. PubMed ID: 17623090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]